Estimated reading time: 2 min On 16 February 2026, the European Commission (the Commission) decided to terminate its antitrust investigation into allegedly anticompetitive behaviour by Edwards Lifesciences (Edwards), based in Irvine, California, which supplies medical devices for cardiovascular applications (see, attached press release).